Interview with Pat Garcia-Gonzalez with GlobalWA

Interview with Pat Garcia-Gonzalez with GlobalWA

For World Cancer Day, GlobalWA interviewed Max CEO Pat Garcia-Gonzalez to hear about the many lessons she has learned in this work, and how both cancer treatment and patients’ access to treatment globally has changed. You can also catch Pat talk on February 12, 2019, at The Pacific Science Center: “the Good, the Bad, and the Ugly.” Pat will discuss the state of global cancer treatment and The Max Foundation’s strategies for removing barriers to access. More information here.

What lessons have you learned in 15+ years working in treatment access?

The first lesson I have learned is that it is possible. It is actually possible to provide access to innovative cancer treatment for patients living in low- and middle-income countries, even when the treatment might be long-term, and in some cases, indefinite. I have also learned that for every patient we are able to rescue, we are not only saving the life of that particular individual, but we are also saving the lives of many others in their family and their communities. We even have a great impact on the availability of oncologists and hematologists by providing the means for them to successfully treat patients and inspiring medical students to want to become oncologists and hematologists.

I have also learned that nothing is simple; these problems are often complex and require great commitment from multiple partners and a great deal of patience, hand-in-hand with a “never give up” attitude.

Finally, I have learned that no matter how hard it is, it is worth it.

What is different from when you started?

So much has changed since we started The Max Foundation. When we first began, targeted cancer therapies didn’t even exist! Then, of course, a miracle happened: Novartis developed imatinib (Glivec®) – this incredible drug that basically changed the nature of chronic myeloid leukemia (CML) turning the diagnosis from a death sentence into a disease that people could live with. Then, just as remarkable, a second miracle – the company decided they would provide access to those in need in low- and middle-income countries. They partnered with us to co-develop what went on to be known as the Glivec® International Patient Assistance Program (GIPAP). In the years that followed, more than 80,000 patients in low- and middle-income countries gained access to treatment through the program.

Read the rest of Pat’s interview on GlobalWA.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • Do Not Lose Heart, Be Positive and Prove Your Mettle

    Do Not Lose Heart, Be Positive and Prove Your Mettle

    Shalet Souza is a 42-year-old nun at the Institute of Sisters of the Little Flower of Bethany, in Mangalore, India. She currently takes care of aspiring nuns and lives a life devoted to learning and supporting others, including the poor and needy in her region. At 29, Shalet sought treatment for frequent fevers, which would….

  • Patient Story: Carmen from the Philippines

    Patient Story: Carmen from the Philippines

    In 2011, Carmen developed a fever that lasted for weeks and began losing weight rapidly. After multiple doctors, tests, and misdiagnoses, she finally discovered she had chronic myeloid leukemia. Carmen feared her life was over. She even went so far as to sew her own funeral dress.

    Eventually, Carmen learned that her cancer could be managed through oral treatment, but the costs were prohibitive. Luckily her physician was a Max Foundation partner. She was able to enroll in our access program for imatinib at no cost, and all seemed well for a few years—until, that is, she stopped responding to her initial treatment.

  • From Depot to Delivered: Expanding Access Through our Supply Chain

    From Depot to Delivered: Expanding Access Through our Supply Chain

    When a doctor requests treatment for a patient in an out-of-reach country, my job is to ensure medicine gets to that patient. Multiply this by 30,000 patients across 70+ countries, and our supply chain becomes a complex system of forecasting demand, requesting donations, shipping medicines, tracking product and confirming deliveries at each destination. I recently….